Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) shot up 9.8% on Thursday . The stock traded as high as $17.78 and last traded at $17.86. 40,203 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 174,658 shares. The stock had previously closed at $16.27.
Wall Street Analysts Forecast Growth
Separately, Oppenheimer began coverage on shares of Pulse Biosciences in a research report on Monday, July 7th. They set an "outperform" rating and a $22.00 price target on the stock. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $22.00.
Read Our Latest Analysis on Pulse Biosciences
Pulse Biosciences Trading Down 4.9%
The stock has a 50 day simple moving average of $15.57 and a 200-day simple moving average of $16.14. The firm has a market cap of $1.19 billion, a P/E ratio of -16.77 and a beta of 1.68.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).
Insider Activity
In related news, Director Robert W. Duggan acquired 34,659 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, September 10th. The shares were purchased at an average price of $14.66 per share, for a total transaction of $508,100.94. Following the completion of the transaction, the director owned 47,551,200 shares in the company, valued at $697,100,592. This represents a 0.07% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO Darrin Uecker sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $16.21, for a total transaction of $324,200.00. Following the sale, the chief technology officer owned 122,872 shares of the company's stock, valued at $1,991,755.12. This represents a 14.00% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 70,000 shares of company stock worth $1,087,950. 74.60% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in PLSE. BNP Paribas Financial Markets boosted its position in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC grew its stake in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock worth $44,000 after purchasing an additional 2,156 shares in the last quarter. AlphaQuest LLC boosted its stake in Pulse Biosciences by 68.0% in the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after acquiring an additional 1,261 shares during the period. PNC Financial Services Group Inc. acquired a new position in Pulse Biosciences during the 1st quarter valued at about $90,000. Finally, GAMMA Investing LLC grew its position in Pulse Biosciences by 2,203.1% in the first quarter. GAMMA Investing LLC now owns 6,034 shares of the company's stock worth $97,000 after buying an additional 5,772 shares during the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
